Analysts expect TransMedics to post earnings of 39 cents a share on revenue of $156 million, representing year-over-year growth of 105% and 28% respectively. Yet the forecast marks a sequential ...
Zacks Investment Research on MSN
TMDX wins full FDA IDE approval for next-gen OCS ENHANCE heart trial
TransMedics TMDX recently announced that it has received full and unconditional FDA Investigational Device Exemption (IDE) ...
TransMedics delivered strong Q2 results, with revenue growth remaining robust and margins improving sharply. While there are concerns around the regulatory environment, competition, and seasonality, ...
OCS Liver adoption surged, with share of total U.S. liver transplants rising from 26% in 2024 to 36% in 2025. Operating margin expanded from 8.5% in 2024 to 18% in 2025, though guidance for 2026 ...
TransMedics Group Inc (NASDAQ:TMDX) stock jumped 6.7% after the company announced that the U.S. Food and Drug Administration (FDA) granted conditional approval for its Investigational Device Exemption ...
TransMedics Group Inc (NASDAQ:TMDX) shares are rising in Wednesday’s after-hours session after the company reported financial results for the second quarter. TMDX stock is surging after hours on ...
Revenue of $157.4M beat by ~7% and EPS of $0.92 more than doubled the $0.43 consensus. Net income jumped +186% YoY, and both service (+44%) and product (+34%) revenue showed strong double-digit growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results